Regarding Today's FDA Hearing On Cannabis-Derived Compounds
A statement from Giadha Aguirre de Carcer Anticipation has been building in the cannabis industry as the U.S. Food and Drug Administration (FDA) meets today regarding how to regulate cannabidiol (CBD), one of the most important compounds in the cannabis plant. CBD is a non-psychotropic cannabinoid, which research has shown to have antiepileptic and anti-inflammatory properties. CBD represents the fastest-growing sector of the global hemp industry and will continue to be a catalyst for the
Read in Benzinga: https://apple.news/AGByEOQr2Mki9h8uqTOnsDg
Shared from Apple News
-Mark
No comments:
Post a Comment